<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03105310</url>
  </required_header>
  <id_info>
    <org_study_id>3636-Med-ERC</org_study_id>
    <nct_id>NCT03105310</nct_id>
  </id_info>
  <brief_title>Pegylated Interferon Alone or in Combination With Ezetimibe for Patients With Chronic Hepatitis D</brief_title>
  <official_title>Pegylated Interferon Alone or in Combination With Ezetimibe for Patients With Chronic Hepatitis D</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aga Khan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aga Khan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ezetimibe possesses pharmacophore features to inhibit NTCP, the receptor required for HBV and
      HDV hepatocyte entry, that include two hydrophobes and one hydrogen bond acceptor.

      The aim of the study io evaluate the utility of Ezetimibe in combination with pegylated
      interferon in patients with chronic HDV infection.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HDV RNA quantitative measurements of &gt;2 logs from baseline</measure>
    <time_frame>24 weeks of therapy</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hepatitis D, Chronic</condition>
  <arm_group>
    <arm_group_label>Pegylated interferon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pegylated interferon alfa alone 180 microgram subcutaneous weekly for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pegylated interferon with ezetimibe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegylated interferon alfa 180 micro-gram subcutaneous weekly for 24 weeks and Ezetimibe 10 mg orally for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated interferon alfa</intervention_name>
    <description>Pegylated interferon alfa</description>
    <arm_group_label>Pegylated interferon</arm_group_label>
    <arm_group_label>Pegylated interferon with ezetimibe</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <description>Ezetimibe</description>
    <arm_group_label>Pegylated interferon with ezetimibe</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of anti-HDV in serum

          -  Presence of quantifiable HDV RNA in serum

          -  Elevated ALT &gt; ULN

        Exclusion Criteria:

          -  Decompensated liver disease

          -  Patients with ALT levels greater than 10 times ULN (400 U/L)

          -  Pregnancy or inability to practice adequate contraception.

          -  Significant systemic or major illnesses other than liver disease, including, but not
             limited to, congestive heart failure, renal failure (eGFR &lt;50 ml/min), organ
             transplantation, serious psychiatric disease or depression and active coronary artery
             disease.

          -  Systemic immunosuppressive therapy

          -  Evidence of another form of liver disease in addition to viral hepatitis

          -  Active substance abuse, such as alcohol or injection drugs

          -  Hepatocellular carcinoma

          -  Concurrent hepatitis C infection or HIV coinfection

          -  Diagnosis of malignancy in the five years

          -  Concurrent usage of statins

          -  Concurrent use of any other drug known to inhibit NTCP

          -  Inability to understand or sign informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2017</study_first_submitted>
  <study_first_submitted_qc>April 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2017</study_first_posted>
  <last_update_submitted>April 3, 2017</last_update_submitted>
  <last_update_submitted_qc>April 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aga Khan University</investigator_affiliation>
    <investigator_full_name>Zaigham Abbas</investigator_full_name>
    <investigator_title>Consultant Gastroenterologist</investigator_title>
  </responsible_party>
  <keyword>Hepatitis D</keyword>
  <keyword>Ezetimibe</keyword>
  <keyword>Pegylated interferon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis D</mesh_term>
    <mesh_term>Hepatitis D, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

